Ascendis Pharma A/S provided an update on its rare disease endocrinology pipeline and presented initial phase 1 data for TransCon PTH, which is in development as a potential treatment for hypoparathyroidism (HP). The company look forward to significant progress during 2018 for rare disease endocrinology pipeline. The company have exceeded target enrollment in the TransCon Growth Hormone pivotal trial and anticipate announcing top-line results in the first quarter of next year. Initial phase 1 data for TransCon PTH support target product profile of TransCon PTH as a true PTH replacement therapy in HP. During the coming year, The company also plan to initiate a phase 1 healthy volunteer trial and present top-line data for TransCon CNP program in achondroplasia.